Richard C. Woodman
Direktor/Vorstandsmitglied bei H3 Biomedicine, Inc.
Profil
Richard C.
Woodman is currently the Director at H3 Biomedicine, Inc. He previously worked as the Senior Director-Medical at Johnson & Johnson from 2002 to 2006, and as the Head-US Oncology Clinical Development at Novartis, Inc. from 2006 to 2018.
He also served as the Chief Clinical Officer-Oncology Business Group at Eisai Co., Ltd.
and as the Chief Medical Officer, SVP-Research & Development at Onconova Therapeutics, Inc. from 2018 to 2021.
Prior to his industry career, he was a Professor at the University of Calgary.
Woodman received his undergraduate degree from the University of British Columbia and his doctorate from the University of Calgary in 1981.
Aktive Positionen von Richard C. Woodman
| Unternehmen | Position | Beginn |
|---|---|---|
H3 Biomedicine, Inc.
 H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Direktor/Vorstandsmitglied | 11.01.2022 |
Ehemalige bekannte Positionen von Richard C. Woodman
| Unternehmen | Position | Ende |
|---|---|---|
| TRAWS PHARMA, INC. | Technik-/Wissenschafts-/F&E-Leiter | 15.01.2021 |
Novartis, Inc.
 Novartis, Inc. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis, Inc. is a company based in San Francisco. | Technik-/Wissenschafts-/F&E-Leiter | 01.03.2018 |
| JOHNSON & JOHNSON | Corporate Officer/Principal | 01.01.2006 |
| EISAI CO., LTD. | Corporate Officer/Principal | - |
| University of Calgary | Corporate Officer/Principal | - |
Ausbildung von Richard C. Woodman
| University of Calgary | Doctorate Degree |
| University of British Columbia | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| TRAWS PHARMA, INC. | Health Technology |
| JOHNSON & JOHNSON | Health Technology |
| EISAI CO., LTD. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Novartis, Inc.
Novartis, Inc. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis, Inc. is a company based in San Francisco. | Health Technology |
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
